Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis

Cutis

Volumn 78, Issue 3, 2006, Pages 178-180

  Prossick, Trisha A ^a   Belsito, Donald V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BIOLOGICAL PRODUCT; HYBRID PROTEIN;

ADULT; ARTICLE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; HAND DISEASE; HOSPITALIZATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PATHOLOGY; PSORIASIS; RECURRENT DISEASE; SKIN DISEASE;

ADULT; BIOLOGICAL PRODUCTS; DIAGNOSIS, DIFFERENTIAL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; PSORIASIS; RECOMBINANT FUSION PROTEINS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 33749248018     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol. 2003;49(suppl 2): S87-S97.
2. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, douhle-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139: 719-727.
3. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003;2: 624-628.
4. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-833.
5. Lebwohl M, Ali S. Treatment of psoriasis, part 2. systemic therapies. J Am Acad Dermatol. 2001;45:649-661.